Ireland
--:--IST
Recruiting Phase 2

A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872 · tracked via the Priya Life Science Spain tracker
Phase
Phase 2
Started
2025-08-19
Last updated
2026-11-12

Condition(s) studied

Type 2 Diabetes Mellitus

Investigational drug(s) / intervention(s)

Tifeglipron →Semaglutide →Placebo

Tifeglipron: Tifeglipron will be taken orally once daily (QD), according to the randomized dosing regimen, during the 30-week treatment period.

Semaglutide: Semaglutide 14 mg will be taken orally QD, with up-titration as per label, during the 30-week treatment period.

Placebo: Placebo matching tifeglipron will be taken orally QD during the 30-week treatment period.

Study summary

This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of different doses of tifeglipron for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Have a diagnosis of Type 2 diabetes mellitus (T2D) for at least 6 months before screening * Have an HbA1c ≥7% and ≤10.5% at screening * Management of T2D with diet and exercise alone or with either a stable dose of metformin or/and sodium-glucose cotransporter-2 (SGLT-2) inhibitors * Body mass index (BMI) ≥23.0 kg/m\^2 at screening * A stable body weight within 3 months prior to screening (maximum 5% self-reported body weight gain and/or loss) Exclusion Criteria: * Have Type 1 diabetes (T1D), history of ketosis or hyperosmolar state/coma, or any other types of diabetes except T2D * Have had 1 or more episodes of Level 3 hypoglycemia or has hypoglycemia unawareness within the 6 months prior to screening * History or presence of proliferative diabetic retinopathy, diabetic macular edema, or non-proliferative diabetic retinopathy that requires acute treatment * Evidence of clinically significant/active nephropathy or neuropathy (including resting tachycardia, orthostatic hypotension, and diabetic diarrhea) * Current treatment or treatment within 3 months of screening with any other anti-hyperglycemic medication except metformin or SGLT-2 inhibitors * Have obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin-4 receptor deficiency or Prader-Willi Syndrome) * Have a known, clinically significant gastric emptying abnormality * Have poorly controlled hypertension at screening, untreated renal artery stenosis, or evidence of labile blood pressure including symptomatic postural hypotension * Have any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)/transient ischemic attack; Unstable angina; Hospitalization due to congestive heart failure

Primary outcome measure(s)

  • Tifeglipron vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30 — Baseline to Week 30

Trial sites (51)

FacilityCityRegionStatus
Arizona Liver Health - Tucson Tucson Arizona Recruiting
Orange County Research Center Lake Forest California Recruiting
Prospective Research Innovations Inc. Rancho Cucamonga California Recruiting
Encompass Clinical Research Spring Valley California Recruiting
Chase Medical Research Waterbury Connecticut Recruiting
Emerson Clinical Research Institute Washington D.C. District of Columbia Recruiting
K2 Medical Research South Orlando, LLC Clermont Florida Active Not Recruiting
Center for Diabetes, Obesity and Metabolism Inc Pembroke Pines Florida Completed
Rophe Adult and Pediatric Medicine/SKYCRNG Union City Georgia Active Not Recruiting
Accellacare of Duly Health and Care Oak Lawn Illinois Active Not Recruiting
Mercury Street Medical Group, PLLC Butte Montana Withdrawn
Neurobehavioral Research, Inc. Cedarhurst New York Completed
Accellacare of Piedmont Healthcare Statesville North Carolina Recruiting
Accellacare of Wilmington, LLC Wilmington North Carolina Recruiting
NexGen Research Lima Ohio Active Not Recruiting
Tristar Clinical Investigations Philadelphia Pennsylvania Recruiting
Alliance for Multispecialty Research. LLC Knoxville Tennessee Withdrawn
Clinical Research Associates Nashville Tennessee Completed
Texas Diabetes & Endocrinology, P.A. Austin Texas Completed
Apex Mobile Clinical Research Bellaire Texas Active Not Recruiting
Velocity Clinical Research Dallas Texas Completed
Velocity Clinical Research (Impact Research Institute) Waco Texas Withdrawn
Chrysalis Clinical Research St. George Utah Completed
Manassas Clinical Research Center Manassas Virginia Recruiting
Obudai Egeszsegugyi Centrum Kft. Budapest Hungary Completed
Qualiclinic Kft. Budapest Hungary Withdrawn
NZOZ Osteo-Medic s.c. A. Racewicz, J.Supronik Bialystok Podlaskie Voivodeship Completed
Centrum Badan Klinicznych PI-House sp. z o.o. Gdansk Pomeranian Voivodeship Active Not Recruiting
Centrum Medyczne INTERCOR Sp. z o.o. Bydgoszcz Poland Active Not Recruiting
Pro Familia Altera Sp z o.o. Katowice Poland Active Not Recruiting
ETG Lublin Lublin Poland Completed
Ekamed sp. z o.o. Lublin Poland Completed
NZOZ METABOLICA Osrodek Badan Klinicznych Tarnów Poland Active Not Recruiting
ETG Warszawa Warsaw Poland Completed
Centrum Badan Klinicznych Wroclaw Poland Active Not Recruiting
ETG Zamosc Zamość Poland Active Not Recruiting
Universidad de Sevilla - Hospital Universitario Virgen Macarena Seville Barcelona Completed
Instituto De Investigacion Marques De Valdecilla (IDIVAL) Santander Cantabria Completed
Hospital Vithas Nisa Sevilla Castilleja de la Cuesta Granada Active Not Recruiting
Hospital Universitario A Coruna A Coruña LA Coruna Active Not Recruiting

+ 11 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07112872 on ClinicalTrials.gov ↗ ← All trials in Spain